Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease - Trial NCT06141070
Access comprehensive clinical trial information for NCT06141070 through Pure Global AI's free database. This Phase 3 trial is sponsored by Vastra Gotaland Region and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 240 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vastra Gotaland Region
Timeline & Enrollment
Phase 3
Dec 01, 2023
Dec 01, 2027
Primary Outcome
Overall survival (OS)
Summary
This is a 2:1 randomized multicentre open label phase III study of radiation combined with
 standard systemic treatment compared with systemic treatment alone in oligometastatic (≤5
 metastases) NSCLC. Stratification factors: performance status, gender and systemic strategy.
 The systemic treatment consists of chemotherapy/chemoimmunotherapy or immunotherapy and is
 given according to local practice. During the first 3 months of systemic treatment, aiming to
 start around the 2nd cycle is radiotherapy delivered to all known lesions. Preferably with
 SBRT /SRT/SRS but conventional radiotherapy may also be used. After the first three cycles of
 systemic treatment, the patients are assessed, and after four cycles, they are continuing
 maintenance therapy if indicated. The patients are followed with radiology every three
 months.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06141070
Non-Device Trial